Mesoblast Limited
Mesoblast Limited (MEOBF) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MEOBF · as of Jun 9, 2026
Key Statistics
Explore Mesoblast Limited Data
meobf stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 33.3%
Competitors & Peers
meobf competitorsMEOBF
BRCTF
CSPHF
GENSF
NURPF
ONTTFStock Performance
Full HistoryAbout Mesoblast Limited
Mesoblast Limited an Australian biopharmaceutical company established in Melbourne in 2004, specializes in the development and global commercialization of allogeneic cellular medicines. With operatio…
what is mesoblast limited · meobf stock overview · mesoblast limited company profile · who is mesoblast limited ceo · meobf OTC · mesoblast limited headquarters · mesoblast limited business segments
About Stock Overview & Key Data
Mesoblast Limited (MEOBF) is a Healthcare company in the Biotechnology industry, listed on OTC since Oct 15, 2010. As of the latest trading session, MEOBF stock price is $1.55, with a market capitalization of $2.0B. The stock has returned +7.64% over the past 12 months and -18.42% year-to-date.
According to 9 Wall Street analysts, the consensus rating for Mesoblast Limited stock is Hold, with an average 12-month price target of $—. In fiscal year 2025, Mesoblast Limited reported revenue of $17.2M and net income of -$102.1M. For detailed data — including Mesoblast Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Mesoblast Limited (MEOBF) stock price is $1.55. The stock is traded on OTC under the ticker symbol MEOBF. The 52-week range is $0.96 – $2.59.